Insight Molecular Diagnostics IMDX
NASDAQ IMDX
$3.44 -0.03 (-0.86%)
At close: Oct 2, 2026 · 4:00 PM EDT

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2022)

Updated

Insight Molecular Diagnostics' Liabilities from Discontinued Operations was $2.01 million in Q4 2022.

Analysis

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 241.25 Bn 220.40 Bn 4.88 Bn
2 Abbott Laboratories 167.33 Bn 138.41 Bn 7.27 Bn
3 Danaher 148.83 Bn 132.65 Bn 3.61 Bn
4 Intuitive Surgical 142.00 Bn 121.55 Bn 1.96 Bn
5 Medtronic 110.70 Bn 76.57 Bn 6.34 Bn
6 Stryker 104.72 Bn 90.84 Bn 4.50 Bn
7 Boston Scientific 62.66 Bn 57.67 Bn 3.85 Bn
8 Edwards Lifesciences 49.13 Bn 33.24 Bn 1.35 Bn
9 Becton Dickinson 48.51 Bn 45.66 Bn 2.32 Bn
10 Insight Molecular Diagnostics 113.20 Mn 36.92 Mn 157,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 2.01 Mn
API Access

Insight Molecular Diagnostics Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=IMDX&period=max&api_key=YOUR_API_KEY